Clinical utility of denosumab for treatment of bone loss in men and women

Robert A Adler
Ranjodh S Gill
Endocrinology and Metabolism, McGuire Veterans Affairs Medical Center, Richmond, VA, USA

Correspondence: Robert A Adler
McGuire Veterans Affairs Medical Center, 1201 Broad Rock Boulevard, Richmond, VA 23249, USA
Tel +1 804 675 5424
Fax +1 804 675 5425
Email robert.adler@va.gov

Abstract: While most older patients with osteoporosis are treated with antiresorptive bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid, such drugs have side effects, remain in bone for extended periods, and lead to poor adherence to chronic treatment. Denosumab is a humanized monoclonal antibody and antiresorptive agent that works by decreasing the activity of the receptor activator of nuclear factor kappa B ligand. In major trials in postmenopausal women, denosumab increased bone mineral density by dual energy x-ray absorptiometry in the spine, hip, and distal third of the radius and decreased vertebral, nonvertebral, and hip fractures. Denosumab is administered by subcutaneous injection every six months, suggesting that adherence may be improved with such therapy. In addition, pharmacokinetic studies measuring bone turnover markers imply that the antiresorptive effect diminishes more quickly over time. Whether these properties will lead to fewer long-term side effects needs to be proven. Denosumab has also been studied in men with prostate cancer treated with androgen deprivation therapy. These men, at high risk for fracture, also have increases in spine, hip, and forearm dual energy x-ray absorptiometry, as well as fewer morphologic vertebral fractures on x-ray. Denosumab is approved for postmenopausal women with osteoporosis in the US and Europe and for men on androgen deprivation therapy in Europe.

Keywords: osteoporosis, fracture, denosumab, bisphosphonates, dual energy x-ray absorptiometry, androgen deprivation therapy, osteonecrosis of the jaw

Introduction

Osteoporosis remains an important problem in older adults in spite of the fact that generally safe and effective therapies are available. Bisphosphonates, including the oral bisphosphonates, ie, alendronate, risedronate, and ibandronate, and intravenous bisphosphonates, including ibandronate and zoledronic acid, are indicated for many patients with osteoporosis. These drugs, while usually well tolerated, have been associated with side effects, such as osteonecrosis of the jaw, atrial fibrillation, and atypical fractures of the femoral shaft. In addition, oral bisphosphonates have been reported to be associated with an increased risk of esophageal carcinoma. While the connection between these side effects and bisphosphonates may not be fully established, and indeed a recent study from Korea suggests that atrial fibrillation may occur less often in patients on bisphosphonates, the incidence of side effects is quite low. Thus, one reason to identify alternative antiresorptive drugs for osteoporosis would be to eliminate or decrease side effects. The mechanism of action and pharmacokinetics of an alternative antiresorptive might also mitigate the side effects. As recently reviewed, studies of bisphosphonates have shown a decrease in fractures of 30%–50% in three-year
studies, but other evidence shows that some bisphosphonates appear safe and effective for 5–10 years. Nonetheless, the optimal length of bisphosphonate treatment remains to be established. It is interesting that while increasing age is a major risk factor for fracture, most bisphosphonate studies did not include the “old old”.

Most bisphosphonates are oral preparations, usually taken weekly or monthly. Because of poor gut absorption, oral bisphosphonates must be taken fasting with only water. Other medications and nutrients must be postponed for at least half an hour. Zoledronic acid is administered as a yearly intravenous infusion. While zoledronic acid is convenient, some patients will have an acute-phase reaction, particularly with the first dose. Perhaps more importantly, adherence to oral bisphosphonates has been poor, whereas long-term adherence to intravenous bisphosphonates has yet to be determined. Patients must take approximately 80% of oral bisphosphonate doses in order to have decreased fracture risk. For the elderly patient with a heavy pill burden, the extra work involved with oral bisphosphonate ingestion may lead to poor adherence. Therefore, alternative antiresorptives that are more likely to result in better treatment persistence are very appealing.

Denosumab is a humanized monoclonal antibody directed against the receptor activator of nuclear factor kappa B ligand (RANKL). Normally, RANKL is produced by osteoblasts and acts through the receptor activator of nuclear factor kappa B (RANK) found on osteoclasts and preosteoclasts. RANKL interacts with RANK to stimulate activation of osteoclasts, leading to augmented bone resorption. Interestingly, there is a decoy receptor, known as osteoprotegerin, that prevents RANKL from interacting with RANK, thus leading to less osteoclast activation.

In some clinical situations, such as postmenopausal osteoporosis, the relation of RANKL to osteoprotegerin is such that osteoclast activity increases, leading to bone loss. Denosumab acts like osteoprotegerin, diminishing osteoclast activity. Unlike bisphosphonates, denosumab does not become incorporated into bone, yielding a much shorter terminal half-life.

Denosumab has the potential to improve adherence to therapy because it is administered as a subcutaneous injection every six months, thus not adding to the pill burden of older patients.

Denosumab has been tested in four Phase III studies in postmenopausal women. The registration trial called FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months) is the largest and most important. In this trial, almost 8000 women were randomized to receive either denosumab 60 mg or placebo by subcutaneous injection every six months for three years. To be included in the study, women aged 60–90 years had to have a bone density T score < −2.5 in the lumbar spine or total hip. Exclusion criteria included a T score < −4, one severe or two moderate prevalent fractures on spine x-ray, or recent exposure to oral glucocorticoids or hormone replacement therapy. All subjects received calcium and vitamin D supplements. The primary outcome was a new vertebral fracture diagnosed by spine x-ray. At three years, 2.3% of the women in the active drug group had a new vertebral fracture compared with 7.2% of placebo subjects. This was a statistically significant 68% relative risk reduction and an almost 5% absolute risk reduction. Clinical vertebral fractures were reduced to approximately the same extent. Nonvertebral fractures were also reduced, ie, by 6.5% versus 8.0%, \( P = 0.01 \). The time to first hip fracture was
significantly shorter in the placebo group. Bone mineral density increased relative to the placebo group by 9.2% (spine) and 6% (total hip). Bone turnover markers reflecting both osteoclastic and osteoblastic activity were suppressed by denosumab compared with placebo. Adverse events included local injection site reactions (0.8% denosumab, 0.7% placebo), eczema (3% denosumab, 1.7% placebo, \( P < 0.001 \)), and cellulitis (0.3% denosumab, <0.1% placebo, \( P = 0.002 \)). No cases of osteonecrosis of the jaw were found, and the overall rates of infection and cancer as adverse events were the same in the active drug and placebo groups.26

A recent post hoc analysis of the FREEDOM trial evaluated fracture incidence in women with known risk factors for fractures, including multiple and/or moderate or severe prevalent vertebral fractures, age 75 years or older, and/or having a femoral neck bone mineral density T score \( \leq -2.5 \).77 Compared with placebo, denosumab significantly reduced the risk of new vertebral fractures in women with multiple and/or severe vertebral fractures (7.5% denosumab versus 16.6% placebo, \( P < 0.001 \)). Similarly, denosumab significantly reduced the risk of hip fractures in subjects aged 75 years or older (0.9% denosumab versus 2.3% placebo, \( P < 0.01 \)) or with a baseline femoral neck bone mineral density T score \( \leq -2.5 \) (1.4% denosumab versus 2.8% placebo, \( P = 0.02 \)). These risk reductions in higher-risk individuals were consistent with those seen in patients at lower risk of fracture.

Osteoporosis is a chronic disorder, and most experts recommend at least five years of bisphosphonate treatment, based on relatively limited data.8,28 The pivotal fracture trial for denosumab described earlier is being followed by a longer-term extension study. In the meantime, there are now some data on up to six years of denosumab treatment. In an extension of a Phase II study, some postmenopausal women have been treated with continuous denosumab or have started denosumab after 1–4 years of placebo treatment (with some subjects having received some years of denosumab or alendronate therapy).29 From the relatively small number of subjects studied, it can be concluded that continuous denosumab leads to further gains of bone mineral density (lumbar spine 2.9%, total hip 1.1%, femoral neck 1.2%, distal third of radius 1% over the two-year extension).29 Bone resorption markers continued to be at about half the level at the original baseline. Without a full placebo group for the two-year extension it is difficult to determine the importance of the adverse events reported. Upper respiratory infections, arthralgias, and back pain were the most common adverse events reported during the extension.

Another study compared the bone density changes over one year in postmenopausal women randomized to denosumab or alendronate.30 At baseline, the women had a T score at the spine or total hip \( \leq -2 \). Women receiving denosumab had increased bone density at the total hip, femoral neck, lumbar spine, and distal third of radius of 3.5%, 2.4%, 5.3%, and 1.1%, respectively, all significantly greater than the changes measured in the women on weekly alendronate (2.6%, 1.8%, 4.2%, and 0.6%, respectively). There were no differences in adverse events between the two treatment groups, although this was only a one-year study with approximately 1200 participants. There is controversy over whether a greater improvement in bone density translates into a greater decrease in fracture risk.31,32 Nonetheless, the robust increase in bone density by denosumab and the fracture decrease reported in the registration trial strengthen the conclusion that denosumab is efficacious.

**Denosumab in androgen deprivation therapy**

Prostate cancer is very common in aging men, and androgen deprivation therapy (ADT) is used in many cases. A man with localized prostate cancer on ADT is at great risk for fracture, as high as 20% over five years, despite having a good overall survival outlook.33–35 Hip fracture in older men has particularly severe consequences. Men aged 75–84 years have a one in three chance of dying by one year after a hip fracture.36 Thus, treatment of older men on ADT might lead to both decreased fracture risk and decreased mortality. Bisphosphonates have been used successfully in men on ADT, but the same potential problems of adherence to therapy may actually be exaggerated in men on ADT.37 After all, they have a cancer, and are affected by the other side effects of ADT.38 Treatment of osteoporosis in such men has no impact on how they feel, unless the treatment prevents a fracture. Convincing a man on ADT to be concerned about his bones is challenging, and persistence in taking a weekly or even monthly oral bisphosphate will likely not be good. While yearly intravenous zoledronic acid works well in such patients, denosumab is also attractive because it can be given subcutaneously at every other administration of ADT therapy, which is usually a gonadotropin hormone-releasing hormone analog provided every three months.39,40 In a study of about 1400 men on ADT, denosumab increased bone density at the spine, hip, and forearm over three years.41 At two years, ie, the primary analysis endpoint, denosumab increased lumbar spine density by 5.6% compared with a
loss of 1% in the placebo group. This 6.7% difference between the active drug and placebo was similar in the total hip (4.8% difference), femoral neck (3.9%), and distal third of radius (5.5%). The difference in the distal third of radius is of particular interest because loss of forearm bone density is common in men on ADT.42 There has been one small study of treatment with denosumab in men with primary osteoporosis, the results of which have not been published yet.

**Place of denosumab in osteoporosis treatment**

**Approved uses**

Denosumab appears to have some potential benefits, only some of which have been studied. First, it is given as a subcutaneous injection in a physician’s office. Thus, for the approved use in postmenopausal women in the US and Europe, it is an attractive drug that might lead to better adherence to therapy. In a study of women treated with denosumab for two years, three months after discontinuation of therapy there was a rise of bone turnover markers above the baseline.43 It is likely that to continue the therapeutic effect would require the patient to return to the clinician’s office for another injection every six months. However, even two years after discontinuation of denosumab, bone mineral density was still higher than in placebo-treated patients.

In Europe, denosumab is approved for men on ADT for prostate cancer. For this indication, the drug is attractive because most of the men on ADT are returning to clinicians’ offices to receive gonadotropin hormone-releasing hormone analog treatment every three months. Hence, treatment of their osteoporosis risk can conveniently be done by denosumab injection every other visit.

**Unapproved uses**

The following scenarios are potential uses for denosumab. These are not approved by government agencies, but might be considered for specific patients. For example, a young woman with asthma requiring glucocorticoids and already having suffered a fragility fracture is at high risk for another fracture.44 While bisphosphonates are used commonly in glucocorticoid-induced osteoporosis, a woman who retains reproductive potential should generally avoid bisphosphonates because they stay in the skeleton, are recirculated, and their effect on the fetal skeleton is unknown. Teriparatide might be considered because it does not linger in the skeleton after treatment.45 Denosumab might also be considered in this situation as well. There is only minimal evidence that denosumab works in glucocorticoid-induced osteoporosis, but it is likely that there will be more studies.46 Another potential patient is a man who has had an allergic reaction to bisphosphonates and is not a candidate for teriparatide. Some patients refuse to take a daily subcutaneous injection. Others may have a contraindication to teriparatide, such as a history of radiation to bone. There are a few patients who have had severe acute-phase reactions to intravenous zoledronic acid and may refuse another infusion. For such patients, offlabel use of denosumab might be considered. It is hoped that more studies of denosumab will be published, so that there will be guidance for the clinician faced with a patient who does not fit into the categories of those studied so far.

**Side effects of denosumab**

As stated earlier, the side effect profile of denosumab has been encouraging from the major published studies. However, the same could be said for the early bisphosphonate trials, and many side effects were only noted after thousands of patients had used bisphosphonates. For example, the original studies of alendronate did not identify any patients with osteonecrosis of the jaw, but of course this has become a well known if unusual side effect. In the registration trial of denosumab, osteonecrosis of the jaw was not seen, but it has been reported more commonly in a similar proportion of patients as with zoledronic acid.47 Hence, we can expect that as many more osteoporosis patients are treated with denosumab, there will be more reports of osteonecrosis of the jaw. The incidence will need to be assessed in comparison with that of other antiresorptive agents. Eczema was noted to occur more frequently in the denosumab subjects (3%) compared with placebo subjects (1.7%) in the pivotal fracture trial.26 Cellulitis was also more common in subjects receiving denosumab (0.3% versus 0.1%).26 In other Phase III studies, infections and neoplasms reported as adverse events were about the same in the active drug and placebo groups. Esophageal carcinoma, which may or may not be associated with oral bisphosphonates, is unlikely to be a problem because denosumab is not an oral medication. Atypical fractures of the femoral shaft have been more recently reported in patients taking long-term bisphosphonates for osteoporosis.36 While the mechanism of these fractures, the true incidence, and specific patient susceptibility to them have not been established, it is possible that such atypical fractures will also be found in patients taking long-term denosumab. As with any new medication, postmarketing
surveillance will be important to determine if there are any unexpected side effects.

**Conclusion**

Denosumab is potentially a very useful medication for osteoporosis because of the convenience of receiving a subcutaneous injection every six months. It appears to be well tolerated overall, and may be more potent than bisphosphonates, but longer-term studies will be necessary to determine long-term safety. Efficacy in the registration trial is impressive, and short-term safety appears to be acceptable. The long-term effect on bone and fracture risk requires continued vigilance. In addition, long-term studies will be needed to show that the apparent convenience of subcutaneous injection every six months leads to better treatment persistence than present bisphosphonate use.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


